Company intelligence / Profile preview

Merxana

Cambridge, Massachusetts, United Statesno.linkedin.com ↗

Ownership: Private
Employees: ~46
Development stage: Other

Overview

Mersana is currently focused on emiltatug ledadotin ("Emi-Le"), a B7-H4-targeting antibody-drug conjugate for triple-negative breast cancer, now in the expansion portion of a Phase 1 study. Initial data show safety and tolerability; further results are expected in 2025. The company has deprioritized other internal R&D to focus resources on this lead asset and supporting partnered programs.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateSmall moleculeBiologic
Industry: Biotech

Partnerships

GSK (option/license for XMT‑2056)Johnson & Johnson/JanssenMerck KGaA

Beyond the preview

Go deeper on Merxana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merxana.

Explore the full profile